glp-1 hormone Science Behind GLP 1 GIP and Glucagon Receptor Agonists for Obesity Research | News & Announcements GLP-1 Agonists - What is

Aleniglipron (Structure Therapeutics) is heading into Phase 3 in mid-2026

For example, one study showed that in people with type 2 diabetes, treatment with semaglutide (1 mg weekly) causes an average loss of about 6% of body weight over 40 weeks, while treatment with tirzepatide (15 mg/week) leads to an 11% weight loss in this population

I., et al., Adjuvant Treatment and Onset of Menopause Predict Weight Gain After Breast Cancer Diagnosis, Journal of Clinical Oncology 17 (1999): 120129

If your state opts in, you could access GLP-1s for weight management at significantly lower cost

Patients considering GLP-1 medications should consult their healthcare provider to discuss whether pharmaceutical intervention is appropriate for their specific clinical situation, including consideration of cardiovascular risk factors, degree of hyperglycemia, and previous response to lifestyle interventions

In line with the latter, GLP-1 have been shown to protect from ischaemia/reperfusion injuries in isolated perfused rat hearts (Bose et al., 2005)